Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mamoru Harada

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Oncology Reports|April 8, 2015
Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cellsTakanobu Motoshima, Yoshihiro Komohara, Hasita Horlad, et al.
Oncology Reports|April 6, 2005
ABCE1, a member of ATP-binding cassette transporter gene, encodes peptides capable of inducing HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes in colon cancer patientsShigeki Shichijo, Yuki Ishihara, Kouichi Azuma, et al.
Fukuoka Igaku Zasshi = Hukuoka Acta Medica|April 23, 2013
Fas-deficient fully allogeneic dendritic cells administered via an intratumoral injection route show efficient antitumor effects in murine modelsShinji Okano, Haruhiko Kondoh, Takeo Toshima, et al.
The Prostate|September 21, 2004
Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patientsMasanori Noguchi, Kyogo Itoh, Akihisa Yao, et al.
Cancer Science|November 29, 2008
Allogeneic cell therapy from immunized donors with tumor antigen peptide enhances the antitumor effect after cyclophosphamide-using non-myeloablative allogeneic hematopoietic cell transplantationMasumitsu Hamaguchi, Masatoshi Eto, Yoriyuki Kamiryo, et al.
International Immunopharmacology|March 4, 2014
Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinomaTakafumi Minami, Tomoko Minami, Nobutaka Shimizu, et al.
International Immunopharmacology|January 23, 2017
Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24<sup>+</sup> patients with renal cell carcinomaTakafumi Minami, Naoki Matsumura, Koichi Sugimoto, et al.
Fukuoka Igaku Zasshi = Hukuoka Acta Medica|April 23, 2013
CD4 T cell-mediated masking effects of the immunogenicity of tumor-associated antigens are qualitatively and quantitatively different depending on the individual antigensShinji Okano, Yoshihiro Matsumoto, Shohei Yoshiya, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 12, 2015
Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell CarcinomaTakafumi Minami, Tomoko Minami, Nobutaka Shimizu, et al.
Pediatric Surgery International|February 12, 2024
The expression analysis of SerpinB9 in hepatoblastoma microenvironmentHiroki Hirao, Ahmad Adawy, Lianbo Li, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Oncology Reports|April 8, 2015
Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cellsTakanobu Motoshima, Yoshihiro Komohara, Hasita Horlad, et al.
Oncology Reports|April 6, 2005
ABCE1, a member of ATP-binding cassette transporter gene, encodes peptides capable of inducing HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes in colon cancer patientsShigeki Shichijo, Yuki Ishihara, Kouichi Azuma, et al.
Fukuoka Igaku Zasshi = Hukuoka Acta Medica|April 23, 2013
Fas-deficient fully allogeneic dendritic cells administered via an intratumoral injection route show efficient antitumor effects in murine modelsShinji Okano, Haruhiko Kondoh, Takeo Toshima, et al.
The Prostate|September 21, 2004
Immunological evaluation of individualized peptide vaccination with a low dose of estramustine for HLA-A24+ HRPC patientsMasanori Noguchi, Kyogo Itoh, Akihisa Yao, et al.
Cancer Science|November 29, 2008
Allogeneic cell therapy from immunized donors with tumor antigen peptide enhances the antitumor effect after cyclophosphamide-using non-myeloablative allogeneic hematopoietic cell transplantationMasumitsu Hamaguchi, Masatoshi Eto, Yoriyuki Kamiryo, et al.
International Immunopharmacology|March 4, 2014
Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinomaTakafumi Minami, Tomoko Minami, Nobutaka Shimizu, et al.
International Immunopharmacology|January 23, 2017
Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24<sup>+</sup> patients with renal cell carcinomaTakafumi Minami, Naoki Matsumura, Koichi Sugimoto, et al.
Fukuoka Igaku Zasshi = Hukuoka Acta Medica|April 23, 2013
CD4 T cell-mediated masking effects of the immunogenicity of tumor-associated antigens are qualitatively and quantitatively different depending on the individual antigensShinji Okano, Yoshihiro Matsumoto, Shohei Yoshiya, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 12, 2015
Identification of Programmed Death Ligand 1-derived Peptides Capable of Inducing Cancer-reactive Cytotoxic T Lymphocytes From HLA-A24+ Patients With Renal Cell CarcinomaTakafumi Minami, Tomoko Minami, Nobutaka Shimizu, et al.
Pediatric Surgery International|February 12, 2024
The expression analysis of SerpinB9 in hepatoblastoma microenvironmentHiroki Hirao, Ahmad Adawy, Lianbo Li, et al.
Pageof 11